drugset / Trial / NCT04977661

Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients

NCT04977661

Phase 4 Completed 102 enrolled Kafrelsheikh University
RandomizedParallel-groupSingle-blindTreatment

Summary

We conducted a 3-month, randomized, single-blind study in 102 Egyptian NASH patients who were divided into three groups; group 1 included 34 patients received Vit. E 400 mg twice a day, group 2 included 34 patients received UDCA 250 mg twice a day and group 3 included 34 patients received PTX 400 mg twice daily for 3 months. The following parameters were measured both before and after intervention intake; liver aminotransferases (AST, ALT), cytokine and chemokine (IL6 and CCL2/MPC-1), albumin, total bilirubin, direct bilirubin, total cholesterol, triglyceride, LDL, HDL.

Timeline

Start
2020-02-01
Primary completion
2020-05-20
Completion
2021-01-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pentoxifylline Small molecule 400 mg
Comparator Ursodeoxycholic Acid Small molecule 250 mg
Comparator Vitamin E Other / unclassified 400 iu